Vor Biopharma Statistics
Share Statistics
Vor Biopharma has 68.67M shares outstanding. The number of shares has increased by 0.87% in one year.
| Shares Outstanding | 68.67M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 59.88M |
| Failed to Deliver (FTD) Shares | 20.11K |
| FTD / Avg. Volume | 3.43% |
Short Selling Information
The latest short interest is 1.71M, so 2.48% of the outstanding shares have been sold short.
| Short Interest | 1.71M |
| Short % of Shares Out | 2.48% |
| Short % of Float | 2.85% |
| Short Ratio (days to cover) | 2.99 |
Valuation Ratios
The PE ratio is -1.28 and the forward PE ratio is -0.83.
| PE Ratio | -1.28 |
| Forward PE | -0.83 |
| PS Ratio | 0 |
| Forward PS | 47.1 |
| PB Ratio | 1 |
| P/FCF Ratio | -1.49 |
| PEG Ratio | n/a |
Enterprise Valuation
Vor Biopharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.04, with a Debt / Equity ratio of 0.24.
| Current Ratio | 9.04 |
| Quick Ratio | 9.04 |
| Debt / Equity | 0.24 |
| Total Debt / Capitalization | 19.13 |
| Cash Flow / Debt | -2.81 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.78% and return on capital (ROIC) is -67.62%.
| Return on Equity (ROE) | -0.78% |
| Return on Assets (ROA) | -0.59% |
| Return on Capital (ROIC) | -67.62% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -701.57K |
| Employee Count | 168 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -56.44% in the last 52 weeks. The beta is -0.41, so Vor Biopharma 's price volatility has been lower than the market average.
| Beta | -0.41 |
| 52-Week Price Change | -56.44% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 1.22 |
| Relative Strength Index (RSI) | 61.19 |
| Average Volume (20 Days) | 587.10K |
Income Statement
In the last 12 months, Vor Biopharma had revenue of $0 and earned -$117.86M in profits. Earnings per share was $-1.75.
| Revenue | 0 |
| Gross Profit | -3.49M |
| Operating Income | -126.04M |
| Net Income | -117.86M |
| EBITDA | -114.37M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.75 |
Balance Sheet
The company has $31.36M in cash and $35.66M in debt, giving a net cash position of -$4.30M.
| Cash & Cash Equivalents | 31.36M |
| Total Debt | 35.66M |
| Net Cash | -4.30M |
| Retained Earnings | -340.08M |
| Total Assets | 115.99M |
| Working Capital | 52.95M |
Cash Flow
In the last 12 months, operating cash flow was -$100.29M and capital expenditures -$1.07M, giving a free cash flow of -$101.36M.
| Operating Cash Flow | -100.29M |
| Capital Expenditures | -1.07M |
| Free Cash Flow | -101.36M |
| FCF Per Share | -1.51 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
VOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -178.57% |
| FCF Yield | -150.61% |
Analyst Forecast
The average price target for VOR is $12, which is 1124.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 1124.5% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -6.94 |
| Piotroski F-Score | 3 |